Prospective cohort study with >10-year follow-up.
To assess the long-term, >10-year clinical outcomes of anterior cervical discectomy and fusion (ACDF) and to compare outcomes based on primary diagnosis of disc herniation, stenosis or advanced degenerative disc disease (DDD), number of levels treated, and preexisting adjacent level degeneration.
ACDF is a proven treatment for patients with stenosis and disc herniation and results in significantly improved short- and intermediate-term outcomes. Motion preservation treatments may result in improved long-term outcomes but need to be compared to long-term ACDF outcomes reference.
Patients who had disc herniation, stenosis, and DDD and underwent ACDF with or without decompression were prospectively enrolled and followed for a minimum of 10 years with outcome assessment at various intervals. All 159 consecutive patients had autogenous tricortical iliac crest bone graft and plate instrumentation used. Outcomes included visual analog scale for neck and arm pain. pain drawing, Oswestry Disability Index, and self-assessment of procedure success. Preoperative adjacent-level disc degeneration, pseudarthrosis, and secondary operations were analyzed.
For all diagnostic groups, significant outcomes improvement was seen at all follow-up periods for all scales relative to preoperative scores. Outcomes were not related to age, gender, number of levels treated, and minimally to preexisting degeneration at the adjacent level. The use of narcotic pain medication decreased substantially. Neurological deficits almost all resolved. Patient self-reported success ranged from 85% to 95%. Over the long term, additional surgery for pseudarthrosis (10%) occurred in the early follow-up period, and for adjacent segment degeneration (21%), which occurred linearly during the >10-year follow-up period.
ACDF leads to significantly improved outcomes for all primary diagnoses and was sustained for >10 years’ follow-up. Secondary surgeries were performed for pseudarthrosis repair and for symptomatic adjacent-level degeneration.
Level of Evidence: 2
Midwest Spine & Brain Institute, Stillwater, MN.
Address correspondence and reprint requests to Glenn R. Buttermann, MD, Midwest Spine & Brain Institute, 1950 Curve Crest Boulevard, Stillwater, MN 55082; E-mail: email@example.com
Received 14 February, 2017
Revised 11 April, 2017
Accepted 12 May, 2017
The device(s)/drug(s) is/are FDA-approved or approved by corresponding national agency for this indication.
Midwest Spine & Brain Institute funds were received in support of this work.
No relevant financial activities outside the submitted work.